Identification of a novel compound that inhibits osteoclastogenesis by suppressing nucleoside transporters

FEBS Lett. 2016 Apr;590(8):1152-62. doi: 10.1002/1873-3468.12146. Epub 2016 Apr 3.

Abstract

We screened small-molecule compounds that inhibit osteoclast differentiation to find new anti-osteoporosis agents and found that a novel compound, SUKU-1, suppressed osteoclastogenesis. We also synthesized 38 derivatives of SUKU-1 and discovered that nine of them had inhibitory effects on osteoclastogenesis and that SUKU-33 was the most potent inhibitor. Next, we investigated the mechanisms by which SUKU-33 suppressed osteoclast differentiation. By measuring the uptake of [(3) H]-uridine in cells, we found that SUKU-33 suppressed both equilibrative nucleoside transporters and concentrative nucleoside transporters. These results suggest that SUKU-33 inhibits osteoclast differentiation by suppressing nucleoside transporters.

Keywords: concentrative nucleoside transporter; equilibrative nucleoside transporter; osteoclast differentiation; osteoporosis.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Female
  • Gene Expression Regulation / drug effects
  • Humans
  • Mice
  • Mice, Inbred ICR
  • Nucleoside Transport Proteins / metabolism*
  • Osteoclasts / drug effects
  • Osteoclasts / metabolism*
  • Osteogenesis / drug effects*
  • Osteogenesis / genetics
  • RANK Ligand / pharmacology
  • RAW 264.7 Cells
  • Signal Transduction / drug effects
  • Small Molecule Libraries / chemistry
  • Small Molecule Libraries / pharmacology*
  • Tritium / metabolism

Substances

  • Nucleoside Transport Proteins
  • RANK Ligand
  • Small Molecule Libraries
  • Tritium